Published online Aug 15, 2020. doi: 10.4251/wjgo.v12.i8.857
Peer-review started: February 10, 2020
First decision: March 24, 2020
Revised: April 6, 2020
Accepted: June 17, 2020
Article in press: June 17, 2020
Published online: August 15, 2020
Processing time: 184 Days and 3.9 Hours
Gastric cancer (GC) is the most commonly diagnosed malignancy worldwide. Increasing evidence suggests that it is necessary to further explore genetic and immunological characteristics of GC.
The prognosis of GC is closely related to the crosstalk between immune cells and tumor cells. Nevertheless, the role of immune-related genes in predicting GC patients’ prognosis has not yet been elucidated.
In this study, we aimed to construct an immune-related gene signature for accurately predicting the prognosis of patients with GC.
Cox univariate survival analysis was performed to screen survival-related immune-related genes (IRGs). Differentially expressed survival-related IRGs were considered as hub IRGs. Hub IRGs were selected to conduct a prognostic signature. Receiver operating characteristic (ROC) curve analysis was performed to evaluate its prognostic performance. The correlation of the signature with clinical features and tumor-infiltrating immune cells was analyzed.
Our study constructed a prognostic signature consisting of ten hub IRGs (including S100A12, DEFB126, KAL1, APOH, CGB5, GRP, GLP2R, LGR6, PTGER3, and CTLA4), and it could be an independent prognostic predictor for GC. Furthermore, it was significantly associated with immune cell infiltration (especially macrophages).
We have proposed an immune-related prognostic signature for GC, which may possess prognostic value as a prediction tool for identification of patients who will benefit from immunotherapy.
The prognostic signature could help develop treatment strategies for patients with GC in the future.
